AGP Executive Report
Last update: 11 hours agoGLP-1 Access Moves Forward: Pfizer’s Ecnoglutide and Innovent’s mazdutide have passed a preliminary review for possible inclusion in China’s basic medical insurance drug catalogue, bringing weight-loss and diabetes treatments closer to reimbursement. Cancer Vaccine Manufacturing: China’s first AI-powered cancer vaccine production line is set to launch in Beijing, signaling a push to speed up next-gen immunotherapy manufacturing. AI in Healthcare, With Scrutiny: A growing debate in China is focusing on how AI is being used in healthcare—and the ethical and data compliance issues that come with it. Medical Innovation Partnerships: Sisram Medical’s China facility has started operations, with its first locally produced Alma Rejuve rolling off the line, while other biotech and device updates point to continued scaling of domestic production. Disaster Response (Public Health Angle): A 5.5-magnitude earthquake hit Sichuan’s Gaoxian County early Monday; no deaths reported and 13 people were treated for minor injuries. Safety Incident: An explosion in a residential building in Liaoning left three missing and eight slightly injured, with suspected liquefied gas leakage under investigation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![[Latest] Global Neonatal Infant Care Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26243376-923052708-north-america-neonatal-infant-care-market-size-2025-to-2035-usd-billion--100x46.png)
